Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cybin Inc
N.CYBN
Alternate Symbol(s):
CYBN
Healthcare
Drug Manufacturers - Specialty & Generic
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary...
deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NEO:CYBN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 27, 2022 8:07am
New Press Release - Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
– Provides access to large catalog of compounds complementary to Company’s preclinical assets –– Strengthens drug discovery and development platform to build future potential novel drug candidates –– Supports broad intellectual property portfolio of innovative psychedelic-based molecules – Cybin...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 27, 2022 7:30am
New Press Release - Mindset Pharma Provides Strategic Intellectual Property License to Cybin
Licensing Subset of Mindset’s Family 1 Intellectual Property Underscores Strength of Mindset’s Portfolio and Business Strategy TORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset”), a drug discovery company developing novel, optimized...
read article.
Silvercorp to Acquire Adventus, Creating a Diversified Mining Company
posted May 02, 2024 9:00am by
Adventus Mining Corp.
-
|
Under the terms of the Arrangement Agreement, each holder of the common shares of Adventus will receive 0.1015 of one Silvercorp common share in exchange for each Adventus Share at the effective time of the Transaction. The Exchange Ratio implies consideration of C$0.50 per Adventus Share ...read more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 21, 2022 8:02am
New Press Release - Cybin to Participate in Upcoming Scientific and Investor Conferences
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to TherapeuticsTM, is pleased to announce its participation in the following upcoming conferences: Interdisciplinary Conference on Psychedelic Research...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 20, 2022 8:05am
New Press Release - Cybin Achieves Research and Development Milestones Ahead of Projected Timelines
-- Completion of Adelia milestones marks promising path toward clinical drug development -- Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, announced that it has successfully achieved its...
read article.
(17)
•••
markovschrilovo
X
View Profile
View Bullboard History
Comment by
markovschrilovo
on Sep 15, 2022 11:46pm
RE:RE:RE:$Silo Wellness' Secret Patent Mushroom Nasal Spray 🍄👃🍄
(13)
•••
DogeCoin
X
View Profile
View Bullboard History
Comment by
DogeCoin
on Sep 12, 2022 9:36pm
RE:RE:RE:$Silo Wellness' Secret Patent Mushroom Nasal Spray 🍄👃🍄
So what your saying is that this company SILO Wellness a nostril sprayy that has psilocybin in it? Jesus, this is pretty dope. Added to my MUSH watchlist. To date so far have not heard of any other
...more
(100)
•••
GajjarDr
X
View Profile
View Bullboard History
Comment by
GajjarDr
on Sep 12, 2022 8:45pm
RE:RE:$Silo Wellness' Secret Patent Mushroom Nasal Spray 🍄👃🍄
https://www.silowellness.com/nasal-spray/ The Company has received feedback from potential licensees with interest in a pharmaceutical use for the nasal spray. Silo Wellness has developed
...more
(17)
•••
Unimaginatively
X
View Profile
View Bullboard History
Comment by
Unimaginatively
on Sep 12, 2022 3:44pm
RE:$Silo Wellness' Secret Patent Mushroom Nasal Spray 🍄👃🍄
(9)
•••
metropop
X
View Profile
View Bullboard History
Comment by
metropop
on Sep 12, 2022 3:39pm
RE:$Silo Wellness' Secret Patent Mushroom Nasal Spray 🍄👃🍄
Hey, thanks alot for Insight! A psilocybin nasal spray sounds promising. I am looking to invest about 5k in the shroom stocks from my recently free cash of 17k float. Any idea when they will be
...more
(13)
•••
ISRAEL
X
View Profile
View Bullboard History
Post by
ISRAEL
on Sep 12, 2022 2:50pm
$Silo Wellness' Secret Patent Mushroom Nasal Spray 🍄👃🍄
Founded in 2018, Silo Wellness offers a diverse and growing portfolio of functional mushroom products, psychedelic wellness retreats in Jamaica and Oregon, cultivation of psychedelic mushrooms and
...more
(16)
•••
realmccoy
X
View Profile
View Bullboard History
Post by
realmccoy
on Sep 10, 2022 4:20am
Next Shroom Stock to Blow: $Silo 𓋼𓋺📈𓋺𓋼 SILO WELLNESS
Volume says it all. Fidelity has been buying major. News Soon :-D
(1831)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Aug 10, 2022 5:22pm
Microdose Announces The 2nd Annual Microdose Awards
Miami, Florida--(Newsfile Corp. - August 9, 2022) - Microdose Psychedelic Insights, the leading guide to the business of psychedelics, is excited to announce the lineup of categories for the 2nd
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 12, 2022 8:12am
New Press Release - Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, announced today that enrollment has begun in a Phase 1/2a clinical trial of CYB003, the first novel psilocybin analog to be...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 11, 2022 7:30am
New Press Release - Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
-- Expected to accelerate clinical development pathway of CYB004 for the potential treatment of anxiety disorders by nine months -- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 27, 2022 7:29pm
New Press Release - Cybin Announces Additional Adelia Milestone Achievement
Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-controlled subsidiary of Cybin, has achieved the milestone identified as...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up
Mullen Group Ltd. Reports 2024 First Quarter Financial Results
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company